Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine with Chemo in Advanced Ovarian Cancer
NCT00373217Phase 2Terminated
- Start
- Apr 2006
- Primary completion
- Feb 2008
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of MAGE-A1 + Her-2/neu + FBP peptides in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms). Primary endpoint: Cytotoxic T-cell Response to Vaccine Therapy Comprising 5 Synthetic Ovarian Cancer-associated Peptides, as Assessed Using Peripheral Blood During Course 1. Started Apr 2006; status: terminated.
02
Drugs
MAGE-A1 + Her-2/neu + FBP peptides
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00373217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373217.